

FORM PTO-1590
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

VGEN.P-055

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/786105

INTERNATIONAL APPLICATION NO.
PCT/CA99/01177INTERNATIONAL FILING DATE
December 10, 1999PRIORITY DATE CLAIMED
December 11, 1998

TITLE OF INVENTION

Method and Kit for the Characterization of Antibiotic-Resistance Mutations ...

APPLICANT(S) FOR DO/EO/US

Robert Shilman

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:



1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

International Preliminary Examination Report

EL556131456US

U.S. APPLICATION NO. 09/786105		INTERNATIONAL APPLICATION NO. PCT/CA99/01177		ATTORNEY'S DOCKET NUMBER VGEN-P-055	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	21 - 20 =	1	x \$18.00	\$ 18.00	
Independent claims	2 - 3 =		x \$80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 878.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+ \$ 439.00	
SUBTOTAL =				\$ 439.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$ 439.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>439.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>15-0610</u> A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: OPPEDAHL & LARSON LLP					
 021121		 SIGNATURE Marina T. Larson, Ph.D.			
PATENT TRADEMARK OFFICE		NAME 32,038 REGISTRATION NUMBER			

VGEN.P-055

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shipman
Serial No. : TBA
Filed : Herewith
Title : Method and Kit for Characterization of Antibiotic-Resistance
Mutations in Mycobacterium Tuberculosis

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

Sir:

Preliminary to the examination of the US national phase of PCT/CA99/01177 which is
filed herewith, please make the following amendments to the claims, as amended before the
IPEA/EP:

In the claims:

In claim 3, line 1, delete "claim 3" and insert -- claim 2 --.

In claim 4, line 1, delete "any of claims 1 to 3" and insert -- claim 1 --.

In claim 5, line 1, delete "any of claims 1 to 4" and insert -- claim 1 --.

In claim 6, line 1, delete "any of claims 1 to 5" and insert -- claim 1 --.

In claim 7, line 1, delete "any of claims 1 to 6" and insert -- claim 1 --.

In claim 8, line 1, delete "any of claims 1 to 7" and insert -- claim 1 --.

In claim 9, line 1, delete "any of claims 1 to 8" and insert -- claim 1 --.

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal
Service as Express Mail # EL55613145648 in an envelope addressed to the Assistant Commissioner of
Patents and Trademarks, Washington, D.C. 20231 on 2/26/2001

Date

Kendra J. [Signature]
Signator

In claim 10, line 1, delete "any of claims 1 to 9" and insert -- claim 1 --.

In claim 11, line 1, delete "any of claims 1 to 10" and insert -- claim 1 --.

In claim 12, line 1, delete "any of claims 2 to 11" and insert -- claim 2 --.

In claim 13, line 1, delete "any of claims 2 to 12" and insert -- claim 2 --.

Please add the following claims:


15. The method of claim 4 wherein the first sequencing procedure for katG is performed using amplification primers as set forth in Seq. ID Nos. 6 and 7 and sequencing primers as set forth in Seq. ID. Nos. 8 and 9.
16. The method of claim 15 wherein the first sequencing procedure for 23S is performed using amplification primers as set forth in Seq. ID. Nos. 46 and 47 and sequencing primers as set forth in Seq. ID. Nos. 48 and 49.
17. The method of claim 16 wherein the second sequencing procedure for PR is performed using amplification primers as set forth in Seq. ID Nos. 11 and 12 and sequencing primers as set forth in Seq. ID. Nos. 13 and 14.
18. The method of claim 17 wherein the second sequencing procedure for pncA is performed using amplification primers as set forth in Seq. ID Nos. 36 and 37 and sequencing primers as set forth in Seq. ID. Nos. 38 and 39.
19. The method of claim 18 wherein the second sequencing procedure for embB is performed using amplification primers as set forth in Seq. ID Nos. 31 and 32 and sequencing primers as set forth in Seq. ID. Nos. 33 and 34.
20. The method of claim 19 wherein the second sequencing procedure for gyrA is performed using amplification primers as set forth in Seq. ID Nos. 41 and 42 and sequencing primers as set forth in Seq. ID. Nos. 43 and 44.
21. The method of claim 20, wherein the third sequencing procedure for 16S/rrs is performed using amplification primers as set forth in Seq. ID Nos. 26 and 27 and sequencing primers as set forth in Seq. ID Nos. 28 and 29.

This amendment has been prepared to eliminate multiple dependencies. No new matter has been

added.

Respectfully submitted,

OPPEDAHL & LARSON LLP

A handwritten signature in cursive script, appearing to read "Marina T. Larson", with a long, sweeping flourish extending to the right.

Marina T. Larson, Ph.D.

Reg. No. 32,038

P.O. Box 5068

Dillon, Co. 80435-5068

- 1 -

**METHOD AND KIT FOR THE CHARACTERIZATION OF
ANTIBIOTIC-RESISTANCE MUTATIONS IN
MYCOBACTERIUM TUBERCULOSIS**

DESCRIPTION

Field of the Invention

This application relates to a method and kit for the characterization of antibiotic resistance mutations in *Mycobacterium tuberculosis*, and particularly to the evaluation of such mutations in clinical samples.

Background of the Invention

M. tuberculosis can be resistant to all antibiotics that are currently used to treat tuberculosis patients. Antibiotic resistance is due to acquired point mutations in target genes in the genome of *M. tuberculosis*. These point mutations render the organism insensitive to the action of the antibiotic by preventing its uptake or activation, or by altering the antibiotic target. The observed antibiotic resistance in *M. tuberculosis* is not due to an episome-encoded resistance gene transferred from one strain to another and, like other bacteria, is single-step (one point mutation), high-level resistance.

Rapid and accurate detection of antibiotic resistance in *Mycobacterium tuberculosis* in sputum samples would greatly improve both patient treatment and outcome. Presently, analysis of *M. tuberculosis* is carried out on DNA recovered from sputum samples handled according to Standard Infectious Disease/Public Health Laboratory practices. The sputum sample is decontaminated and a cell sediment isolated. This cell sediment is the sample source for all routine procedures used in the detection and isolation of *M. tuberculosis*. Portions of this sample are used in BacTec cultures for selective growth of *M. tuberculosis*, agar plate/agar slant cultures for *M. tuberculosis*, acid-fast bacilli (AFB) smears for mycobacteria detection and molecular biological methods for the detection of *M. tuberculosis* and atypical mycobacteria. (See Fig. 1)

Mycobacterial DNA is prepared directly from the decontaminated sputum cell sediments according to standard procedures and this mycobacterial DNA is used in the various molecular biological detection procedures. The methods presently in use for the detection of *M. tuberculosis* are either PCR-based or probe-based. These tests are used

primarily on AFB smear-positive samples. Since the presence of *M. tuberculosis* has already been established by the AFB smear, these tests are used primarily in a confirmatory capacity as opposed to a diagnostic capacity. Furthermore, these tests provide no information on the potential antibiotic resistance of these *M. tuberculosis* samples.

Below is a list of antibiotics used to treat *M. Tuberculosis* infections. The gene target of the specific antibiotic and regions associated with antibiotic resistance are listed, if known. The references on which the codon assignments are based are listed at the end of the application.

1.	Rifampin	rpoB gene	codon 507-533 ^a
2.	Isoniazid	katG gene	codon 275/315/328 ^b
3.	Isoniazid	mabA gene	unknown ^a
4.	Isoniazid	oxyR-ahpC intergenic region (PR)	nucleotides -48 to +33
5.	Azithromycin	23S rRNA sequence	nucleotide 2568A ^c
6.	Pyrazinamide	pncA gene	codon 47/85 ^f
7.	Ethambutol	embB gene	codon 306 ^g
8.	Streptomycin	rpsL/s12 gene	codon 43/88 ^h
9.	Streptomycin	16S/rrs sequence	nucleotides 491, 512, 516, 513, 903, 904
10.	Ciprofloxacin	gyrA gene	codon 88-95 ^j

Probe-based tests do exist for the determination of rifampin resistance in *M. tuberculosis* (line probe assay-InnoTect), but these probes rely on prior knowledge of antibiotic resistance-associated mutations in the rpoB gene. Mutations outside the region covered by the probe or new mutations not included in the probe cocktail could still confer resistance, but would not be detected using this product in its present form.

Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy", vol. 34, page 163 (1994) describes the application of automated DNA sequence analysis of *hsp65* to speciation of isolates previously-identified as being *M. tuberculosis*.

Thus, there remains a need for a method for detecting antibiotic-resistance mutations in clinical *M. tuberculosis* sputum samples which is capable of detecting mutations in all of the gene targets which confer antibiotic resistance. It is an object of the present invention to provide such a method. It is a further object of this invention to provide amplification and cycle sequencing primer sets, and kits containing such primer sets, for use in the characterization of antibiotic resistance mutations in *M. tuberculosis*.

Summary of Invention

Amplification and cycle sequencing primer sets have been developed for the detection and analysis of antibiotic resistance-associated mutations in defined regions of the *rpoB* (rifampin), *katG* (isoniazid), *oxyR-ahpC* PR (isoniazid), *mabA* (isoniazid), *rpsL/s12* (streptomycin), *16S/rrs* (streptomycin), *embB* (ethambutol), *pncA* (pyrazinamide), *gyrA* (ciprofloxacin) and *23S* (azithromycin) genes. Using these primer sets and the OPENGENTM automated DNA sequencing system, a protocol has been developed which permits both the rapid detection of *M. tuberculosis* and the identification of antibiotic resistance-associated mutations in a series of gene targets. The present invention uses a series of tests designed to detect antibiotic resistance-associated mutation in all gene targets for all antibiotics presently in use for the treatment of tuberculosis. The tests are employed in a hierarchical manner on both AFB smear-positive or smear-negative samples to determine both the presence and antibiotic-resistance of *M. tuberculosis* in a given sample. This method permits the simultaneous determination of *M. tuberculosis* presence in a sample and the antibiotic-resistance profile to an entire panel of antibiotics. Standard methods require from 2-6 weeks to culture *M. tuberculosis* and additional time to establish antibiotic resistance. Although DNA sequence-based (genotypic) tests are not intended to replace the traditional culture-based (phenotypic) methods, these tests do represent a rapid, sensitive and accurate protocol which provides clinicians with valuable information regarding antibiotic treatment options within days as opposed to weeks.

Brief Description to the Figures

Fig. 1 shows known testing protocols for *M. tuberculosis*, and

Fig. 2 shows a hierarchical assay scheme for evaluating *M. tuberculosis* type in accordance with the invention.

Detailed Description of the Invention

In accordance with the invention, regions of the genome of *M. tuberculosis* associated with antibiotic resistance are amplified and sequenced using specifically designed amplification and sequencing primers. Various techniques for amplification are known, including the basic PCR amplification techniques described in US Patent No. 4,683,202, which is incorporated herein by reference. Similarly, various techniques for sequencing are known, some of which require prior amplification and some of which do not. Included among known sequencing techniques are those disclosed in US Patents Nos. 5,834,189 and 5,789,168, which are incorporated herein by reference. The primers of the invention can be used in any of these sequencing formats, although the invention is exemplified below using separate amplification and cycle-sequencing steps.

In theory, the selection of primers to amplify and sequence a known region of interest should be straightforward. In fact, however, because of the possibility of primer binding to other sites, complications arising from secondary structure, and other factors which are not fully understood, some primers perform better than others for amplification and sequencing of the same region of interest. The present invention provides primers which have been optimized for the amplification and sequencing of regions associated with each of the ten known types of antibiotic resistance. These primer sets are shown below, along with the sequence of the genes that they are used to analyze. In the gene sequences, the locations of the primers are underlined.

Primers

rpoB (rifampin resistance)

rpoB-F amplification primer, 20-mer, bp2201-2220

5' TAC GGT CGG CGA GCT GAT CC 3'

SEQ. ID NO. 1

rpoB-R amplification primer, 20-mer, bp2611-2592

5' TAC GGC GTT TCG ATG AAC CC 3'

SEQ ID NO. 2

- 5 -

rpoB-5s sequencing primer, 20-mer, bp2201-2220

5' TAC GGT CGG CGA GCT GAT CC 3'

SEQ ID NO. 3

rpoB-3s sequencing primer, 20-mer, bp2611-2592

5' TAC GGC GTT TCG ATG AAC CC 3'

SEQ ID NO. 4

SEQ. ID. NO. 5

2161 aaaccgacga catcgaccac ttcggcaacc gccgcctgcg ~~tacggtcggc gacgtgatcc~~
 2221 aaaaccagat cggggtcggc atgtcgcgga tggagcgggt ggtccgggag cggatgacca
 2281 ccaggacgt ggaggcgatc acaccgcaga cgttgatcaa catccggcgg gtggtcgccg
 2341 cgatcaagga gttcttcggc accagccagc tgagccaatt catggaccag aacaaccgcg
 2401 tgtcgggggtt gaccacaag cgccgactgt cggcgctggg gcccgccgggt ctgtcacgtg
 2461 agcgtgcggg gctggaggtc cgcgacgtgc acccgtcgca ctacggccgg atgtgccgga
 2521 tcgaaacccc tgagggggccc aacatcggtc tgatcggtc gctgtcggtg tacgcgcggg
 2581 tcaaccgggt cgggttcctc gaaacgccgt accgcaaggt ggtcgacggc gtggttagcg

katG (isoniazid resistance)

katG-F amplification primer, 20-mer, bp722-741

5' ATG GGG CTG ATC TAC GTG AA 3'

SEQ ID NO. 6

katG-R amplification primer, 20-mer, bp1250-1231

5' GGT GTT CCA GCC AGC GAC GC 3'

SEQ ID NO. 7

katG-5s sequencing primer, 20-mer, bp722-741

5' ATG GGG CTG ATC TAC GTG AA 3'

SEQ ID NO. 8

katG-3s sequencing primer, 20-mer, bp1250-1231

5' GGT GTT CCA GCC AGC GAC GC 3'

SEQ ID NO. 9

SEQ ID NO. 10

661 gctcggcgat gagegttaca gcggtaagcg ggatctggag aaccgcgtgg ccgcgggtgca
 721 gatggggctg atctactgta acccgagggg gccgaacggc aaccgggacc ccatggccgc
 781 ggcggctgac attcgcgaga cgtttcggcg catggccatg aacgacgtcg aaacagcgcc
 841 gctgatcgtc ggcgggtcaca ctttcggtaa gaccatggc gccggccggc ccgatctggt
 901 cggccccgaa ccgagggtcg ctccgctgga gcagatgggc ttgggctgga agagctcgta
 961 tggcaccgga accggtaagg acgcgatcac cagcggcctc gaggtcgtat ggacgaacac
 1021 cccgacgaaa tgggacaaca gtttcctcga gatcctgtac ggctacgagt gggagctgac

- 6 -

1081 gaagagccct gctggcgctt ggcaatacac cgccaaggac ggccgccgtg ccggcaccat
 1141 cccggagccg ttcggcgggc cagggcgctc cccgacgatg ctggccactg acctctcgct
 1201 gcgggtggat ccgatctatg agcggatcac gcgtcgctgg ctggaacacc ccgaggaatt
 1261 ggccgacgag ttcgcccaagg cctggtacaa gctgatccac cgagacatgg gtccccgtgc

oxyR-aphC intergenic region (PR)

PR-F amplification primer, 20-mer, bp451-470

5' ACC ACT GCT TTG CCG CCA CC 3' SEQ ID NO. 11

PR-R amplification primer, 20-mer, bp687-668

5' CCG ATG AGA GCG GTG AGC TG 3' SEQ ID NO. 12

PR-5s sequencing primer, 20-mer, bp451-470

5' ACC ACT GCT TTG CCG CCA CC 3' SEQ ID NO. 13

PR-3s sequencing primer, 20-mer, bp687-668

5' CCG ATG AGA GCG GTG AGC TG 3' SEQ ID NO. 14

SEQ ID NO. 15

361 atgccctggg ggtgcaccga gaccggcttc cgaccaccgc tcgccgaac gtcgactggc
 421 tcatactgag aatgcttgcg gcaactgctga accactgctt tgcggccacc gcggcgaacg
 481 cgcgaagccc ggccacggcc ggctagcacc tcttgccgcg gatgccgata aatatgggtg
 541 gatatactac ctttgccctga cagcgacttc acggcacgat ggaatgtcgc aaccaaattgc
 601 attgtccgct ttgatgatga ggagagtcac gccactgcta accattggcg atcaattccc
 661 cgccctacag ctcaccgctc tcacggcg tgacctgtcc aaggtcgacg ccaagcagcc
 721 cgccgactac ttcaccacta tcaccagtga cgaacacca ggcaagtggc ggggtggtgt

mabA (isoniazid resistance)

mabA-F amplification primer, 20-mer, bp56-75

5' CCT CGC TGC CCA GAA AGG GA 3' SEQ ID NO. 16

mabA-R amplification primer, 20-mer, bp303-284

5' ATC CCC CGG TTT CCT CCG GT 3' SEQ ID NO. 17

mabA-5s sequencing primer, 20-mer, bp56-75

5' CCT CGC TGC CCA GAA AGG GA 3' SEQ ID NO. 18

- 7 -

mabA-3s sequencing primer, 20-mer, bp303-284

5' ATC CCC CGG TTT CCT CCG GT 3'

SEQ ID NO. 19

SEQ ID NO. 20

```

1   agcgcgacat acctgctgcg caattcgtag ggcgtcaata caccgcgacg cagggcctcg
61  ctgcccagaaa agggatccgt catggtcgaa gtgtgctgag tcacaccgac aaacgtcacg
121 agcgtaaccc cagtgcgaaa gttcccgcgc gaaatcgcag ccacgttacg ctctgtggaca
181 taccgatattc ggcccgggcgc cggcgagacg ataggttgct ggggtgactg ccacagccac
241 tgaaggggcc aaaccccatc tcgtatccgc ttcagtcctg gttaccggag gaaacccggg
301 gatcgggctg gcgatcgac agcgggtggc tgccgacggc cacaaggtgg ccgtcaccca

```

rpsL/s12 (streptomycin resistance)

s12-F amplification primer, 20-mer, bp1-20

5' CGG TAG ATG CCA ACC ATC CA 3'

SEQ ID NO. 21

s12-R amplification primer, 20-mer, bp384-365

5' GCA TCA GCC CTT CTC CTT CT 3'

SEQ ID NO. 22

s12-5s sequencing primer, 20-mer, bp1-20

5' CGG TAG ATG CCA ACC ATC CA 3'

SEQ ID NO. 23

s12-3s sequencing primer, 20-mer, bp384-365

5' GCA TCA GCC CTT CTC CTT CT 3'

SEQ ID NO. 24

SEQ ID NO. 25

```

1   cggtagatgc caaccatcca gcagctggtc cgcaagggtc gtcgggacaa gatcagtaag
61  gtcaagaccg cggctctgaa gggcagccgc cagcgtcgtg gtgtatgcac ccgcgtgtac
121 accaccactc gaaagaagcc gaactcggcg cttcggaagg ttgcccgctg gaaattgacg
181 agtcaggctg aggtcacggc gtacattccc ggcgaggggc acaacctgca ggagcactcg
241 atgggtgctg tgcgcggcgc ccgggtgaag gacctgcctg gtgtgcgcta caagatcatc
301 cgcggttcgc tggatacgca ggggtgcaag aaccgcaaac aggcacgcag ccgttacggc
361 gctaagaagg agaagggtcg atgccacgca aggggcccgc gcccaagcgt ccgttggtca

```

16S/rrs (streptomycin resistance)

16S-F amplification primer, 21-mer, bp5-25

5' GGT GAT CTG CCC TGC ACT TCG 3'

SEQ ID NO. 26

16S-R amplification primer, 21-mer, bp147-127

- 8 -

5' CGT CAC CCC ACC AAC AAG CTG 3' SEQ ID NO. 27
 16S-5s sequencing primer, 21-mer, bp5-25
 5' GGT GAT CTG CCC TGC ACT TCG 3' SEQ ID NO. 28
 16S-3s sequencing primer, 21-mer, bp147-127
 5' CGT CAC CCC ACC AAC AAG CTG 3' SEQ ID NO. 29

SEQ ID NO. 30

1 cgtgggtgat ctgccctgca cttcgggata agcctgggaa actgggtcta ataccggata
 61 ggaccacggg atgcatgtct tgtggtggaa agcgctttag cggtgtggga tgagcccgcg
 121 gcctatcagc ttgttgggtgg ggtgacg

embB (ethambutol resistance)

embB-F amplification primer, 21-mer, bp7761-7781

5' CGG CAA GCT GGC GCA CCT TCA 3' SEQ ID NO. 31

embB-R amplification primer, 21-mer, bp8040-8020

5' AGC CAG CAC ACT AGC CCG GCG 3' SEQ ID NO. 32

embB-5s sequencing primer, 21-mer, bp7761-7781

5' CGG CAA GCT GGC GCA CCT TCA 3' SEQ ID NO. 33

embB-3s sequencing primer, 21-mer, bp8040-8020

5' AGC CAG CAC ACT AGC CCG GCG 3' SEQ ID NO. 34

SEQ ID NO. 35

7741 cggcatgcgc cggctgattc cggcaagctg gcgcaccttc accctgaccg acgcogtgg
 7801 gatattcggc ttctctgtct ggcattgcat cggcgcgaaat togtcggacg acggtacat
 7861 cctgggcatg gcccagatcg cgcaccacgc cggctacatg tccaactatt tccgctgggt
 7921 cggcagcccg gaggatccct tcggctggta ttacaacctg ctggcgctga tgacccatgt
 7981 cagcgacgcc agtctgtgga tgcgcctgcc agacctggcc gcgcggctag tctgctggc

pncA (pyrazinamide resistance)

pncA-F amplification primer, 20-mer, bp1-20

5' ATG CGG GCG TTG ATC ATC GT 3' SEQ ID NO. 36

- 9 -

pncA-F amplification primer, 20-mer, bp561-542

5' TCA GGA GCT GCA AAC CAA CT 3'

SEQ ID NO. 37

pncA-5s sequencing primer, 20-mer, bp1-20

5' ATG CGG GCG TTG ATC ATC GT 3'

SEQ ID NO. 38

pncA-3s sequencing primer, 20-mer, bp561-542

5' TCA GGA GCT GCA AAC CAA CT 3'

SEQ ID NO. 39

SEQ ID NO. 40

1 atcgggcggt tgatcatcgt cgacgtgcag aacgacttct gcgagggtgg ctgcgtggcg
 61 gtaaccgggtg gcgcgcgcgt ggcccgcgcc atcagcgact acctggccga agcggcggac
 121 taccatcacg tcgtggcaac caaggacttc cacatcgacc cgggtgacca ctctccggc
 181 acaccggact attctctgtc gtggccaccg cattgcgtca gcggtactcc cggcgcggac
 241 ttccatccca gtctggacac gtcggcaatc gaggcggtgt tctacaaggg tgccctacacc
 301 ggagcgtaca gcggtctcga aggagtcgac gagaacggca cgccactgct gaattggctg
 361 cggcaacgcg gcgtcgatga ggtcgatgtg gtcggtattg ccaccgatca ttgtgtgcgc
 421 cagacggccg aggaacgcgt acgcaatggc ttggccacca ggggtctggt ggacctgaca
 481 gcgggtgtgt cggccgatac caccgtcgcc gcgctggagg agatgcgcac gccacgcgtc
 541 gagttggtt gcagctcctg a

gyrA (fluoroquinilone/ciprofloxacin resistance)

gyrA-F amplification primer, 20-mer, bp2383-2402

5' CAG CTA CAT CGA CTA TGC GA 3'

SEQ ID NO. 41

gyrA-R amplification primer, 20-mer, bp2702-2683

5' GGG CTT CGG TGT ACC TCA TC 3'

SEQ ID NO. 42

gyrA-5s sequencing primer, 20-mer, bp2383-2402

5' CAG CTA CAT CGA CTA TGC GA 3'

SEQ ID NO. 43

gyrA-3s sequencing primer, 20-mer, bp2702-2683

5' GGG CTT CGG TGT ACC TCA TC 3'

SEQ ID NO. 44

SEQ ID NO. 45

2341 cgaccggatc gaaccggttg acatcgagca ggagatgcag cgcagctaca tcgactatgc
 2401 gatgagcgtg atcgtcggcc gcgcgctgcc ggagggtcgc gacgggctca agcccgtaga
 2461 tcgcccgggtg ctctatgcaa tgttcgattc cggcttcgcg ccggaccgca gccacgccaa

- 10 -

2521 gtcggcccg tccgttgccg agaccatggg caactaccac ccgcacggcg acgcgtcgat
 2581 ctacgacagc ctggtgcgca tggcccagcc ctggtcgctg cgctaccgcg tggaggacgg
 2641 ccagggaac ttcggctcgc caggcaatga cccaccggcg gcgatgaggt acaccgaagc
 2701 ccggctgacc ccgttgccga tggagatgct gagggaaatc gacgaggaga cagtcgattt

23S (macrolide/azithromycin resistance)

23S-F amplification primer, 20-mer, bp2444-2463

5' CGA AAT TCC TTG TCG GGT AA 3'

SEQ ID NO. 46

23S-R amplification primer, 20-mer, bp2683-2664

5' GTA TTT CAA CAA CGA CTC CA 3'

SEQ ID NO. 47

23S-5s sequencing primer, 20-mer, bp2444-2463

5' CGA AAT TCC TTG TCG GGT AA 3'

SEQ ID NO. 48

23S-3s sequencing primer, 20-mer, bp2683-2664

5' GTA TTT CAA CAA CGA CTC CA 3'

SEQ ID NO. 49

SEQ ID NO. 50

2401 gccccagtaa acggcggtgg taactataac catcctaagg tagcgaatt ccttgcggg
 2461 taagttccga cctgcacgaa tggcgtaacg acttcccaac tgtctcaacc atagactcgg
 2521 cgaattgca ctacgagtaa agatgctcgt tacgcgcggc aggacgaaaa gaccccgga
 2581 ccttactac aacttggtat tgggttcgg tacggttctg gtaggatagg tgggagactt
 2641 tgaagcacag acgccagttt gtgtggagtc gttgtgaaa taccactctg atcgtattgg

To facilitate detection of the sequencing products using real-time fluorescence-based electrophoresis apparatus (for example, a Visible Genetics OPENGENTM sequencer), at least one of the sequencing primers is preferably labeled with a fluorescent label. The label is selected for compatibility with the sequencing apparatus employed, and may be, for example, fluorescein or a cyanine dye such as CY5.0 OR CY5.5.

The primers of the invention are suitably packaged in a kit. This kit will contain individually packaged amplification and sequencing primers sets for each resistance gene to be evaluated by the kit. Thus, the kit of the invention includes at least 4 primers (two amplification and two sequencing primers), and preferably includes the primer sets for a plurality of resistance genes, most preferably the primer sets for all ten resistance genes.

The suitable protocol for the utilization of these primer sets in the evaluation of *M. tuberculosis* in clinical samples utilizes PCR amplification, followed by cycle sequencing. DNA for use in the test is obtained from a sample of sputum (100ul-10ml). The sputum sample is processed according to Standard Infectious Disease/Public Health Laboratory practices (Mycobacteriology Bench Manual, Laboratory Services Branch, December 1997, Ontario Ministry of Health). The sputum sample is homogenized, decontaminated and concentrated. Mycobacterial DNA is prepared directly from a portion of the concentrated cell sediment (100-200ul) using standard DNA extraction methods or commercially available kits.

Amplification of the DNA is performed using the amplification primer sets described above. PCR reagents can be prepared for individual reactions, or may be prepared as a master mix which can be used for multiple tests e.g., 10 PCR reactions. Exemplary combinations of reagents are summarized in the following table.

PCR mix		1 PCR	10 PCRs	final conc. / PCR
genomic DNA	(20ng/ul)	1.0ul		20ng
(~0.5fM)				
10X PCR buffer I		2.5ul	25.0ul	1X
2.5mM dNTP mix	(1:1:1:1)	2.5ul	25.0ul	250uM
DMSO		1.3ul	13.0ul	5%
Taq DNA polymerase (1U)		0.2ul	2.0ul	1 unit
molecular grade water		16.5ul		165.0ul
MTB gene primers	(10uM)	1.0ul	10.0ul	10pmol per primer
total volume per PCR		25.0ul		

If the master mix as shown in the column labeled 10 PCRs is utilized, the mastermix contains all the necessary PCR reagents other than the genomic DNA. In this example, 24.0ul of the mastermix is added to a PCR tube, that already contains 1.0ul of genomic DNA, prior to the addition of the mineral oil overlay and placement in the thermocycler.

The genomic DNA preparation utilized must be of sufficient quality and integrity for robust and reproducible PCR. Suitable DNA preparation can be obtained using

- 12 -

the Gentra Puregene™ DNA isolation kit. The kit components are appropriate for the isolation of genomic DNA from blood, fresh or frozen tissue, archival material and paraffin-embedded tissue.

Each primer pair is used to amplify a single gene region under the following conditions:

1.	Denaturation	94°C	5 minutes	1 cycle
2.	Denaturation	94°C	30 seconds	
	Annealing	60°C	30 seconds	35 cycles
	Extension	72°C	60 seconds	
3.	Extension	72°C	5 minutes	1 cycle
4.	Hold	6°C		

The temperature change during the cycles of the step 2 is desirably set to ramp at a rate of 1°C/sec.

After amplification, 2.0ul from the 25.0ul PCR is analysed for purity on a 0.8% agarose gel. Samples displaying single PCR product bands can be used directly for sequence analysis. The yield and purity of the PCR product determines the amount to be used in the subsequent cycle sequencing reaction. Comparable verification of sequencing purity is performed on each of the other amplification products.

Sequence analysis is carried out on the amplified product. The basic procedures and conditions are the same for each region. Accordingly, the invention will be exemplified using the rpoB gene.

For initial sequence analysis of rpoB, the rpoB-5s primer should be used. For confirmatory sequence analysis the rpoB-3s primer should be used. For each template to be sequenced, aliquot 3.0ul of each of the nucleotide termination mixes into four separate tubes marked <A>, <C>, <G> and <T> and store on ice until the sequencing mastermix is prepared.

Cycle sequencing mastermix

rpoB template	2.0ul
10X VGI Sequenace™ buffer	2.5ul

- 13 -

DMSO	3.5ul
2.5uM dye-sequencing primer	2.0ul
PCR grade water	9.0ul
<u>1:10 diluted Thermostase</u>	<u>0.5 ul</u>
total volume	22.0ul

Mix the DMSO and other components in the mastermix well by repeated pipetting (5 times) with a micropipette. Store the mastermix on ice until ready to add to the nucleotide termination mixes.

Add 5.0ul of the mastermix to each of the four marked tubes containing the nucleotide termination mixes.

Add 8.0ul lightweight mineral oil to each of the four marked tubes containing the mastermix and nucleotide termination mixes.

Store on ice until ready to load into the thermocycler.

Parameters for cycle sequencing

1.	Denaturation	94°C	5 minutes	1X
2.	Denaturation	94°C	30 seconds	
	Annealing	60°C	30 seconds	35X
	Extension	72°C	60 seconds	
3.	Extension	72°C	5 minutes	1X
4.	Hold	6°C		

The temperature change during the cycles of the step 2 is desirably set to ramp at a rate of 1°C/sec.

At the end of the cycle sequencing reaction add 6.0ul of the Stop Loading Dye directly to each of the four tubes to stop the sequencing reaction. The sequencing samples are heated at 95°C for 2 minutes and then placed on ice before loading 2.0ul (from a total volume of 14ul) on the CLIPPER™ sequencer. The remainder of the sequencing reaction can be stored at -20°C for subsequent use.

- 14 -

The CLIPPER™ sequencer is set-up as described in the *OPENGENE Automated DNA Sequencing System User Manual*. Run parameters for the CLIPPER™ sequencer are 54°C/ 1300volts/ 0.5sec sampling/35min run/50% laser power. The samples loaded included 2 ul each of the forward and reverse sequencing reaction products for the target gene, differentially labeled, for example with CY5.0 and CY5.5 cyanine dye labels. Once the run is completed, the base-called data is analysed by comparison of the test sequence to the rpoB sequence database in GENELIBRARIAN™. This sequence alignment compares the test sequence to the standard control sequence and allows sequence ambiguities to be assessed. Once edited the test sequence can be screened for antibiotic resistance-associated mutations using GENELIBRARIAN™.

Testing for multiple types of antibiotic-resistance mutations can be carried out using a hierarchical assay, as summarized in Fig. 2. At present molecular biological methods for the detection of *M. tuberculosis* are only performed on AFB smear-positive sputum samples. These methods serve as confirmatory tests for the presence of *M. tuberculosis*. In addition to these molecular biological methods, the culture-based procedures for *M. tuberculosis* detection (BacTec liquid culture, agar plate and slant cultures) are performed in parallel. AFB smear-negative sputum samples are processed with only the culture-based detection procedures (Figure 1).

In the present invention both AFB smear-positive and smear-negative sputum samples can be processed using both culture-based and molecular biological methods. A limitation of the AFB stain methodology is its limit of detection. If a sputum sample has a mycobacterial concentration of less than 5000 bacteria/ul the AFB stain will be negative. In addition to this is the observation that the decontamination procedure used to prepare the sputum sample usually kills 10-20% of the mycobacteria present. This would suggest that two-thirds of the AFB smear-negative samples potentially contain mycobacteria. In practice 10-20% of the AFB smear-negative samples are culture-positive for *M. tuberculosis* (Ontario Public Health Laboratory). This level of mycobacteria is easily detected by molecular biological methods and is therefore incorporated in the present invention.

The hierarchy proposed incorporates tests that specifically detect *M. tuberculosis* (rpoB), detect mutations in genes associated with resistance to the "first-line" antibiotics used to treat *M. tuberculosis* infections (rpoB, katG, rpsL/s12, PR, embB, pncA)

and detect other species of mycobacteria (23S) in the absence of *M. tuberculosis* (Figure 2). Group I analyses are performed before both Group II and Group III. Group I analysis will provide information on the antibiotic resistance status to rifampin (rpoB), isoniazid (katG), streptomycin (rpsL/s12) and azithromycin (23S). In addition the rpoB amplification indicates the presence of *M. tuberculosis* and in the absence of rpoB amplification the 23S sequence allows identification of most of the clinically relevant mycobacterial species. Group II analysis provides information on antibiotic resistance mutations in the "second-line" antibiotics used to treat *M. tuberculosis* infections namely, isoniazid (PR), ethambutol (embB), pyrazinamide (pncA) and ciprofloxacin (gyrA). Group III contains gene targets in which mutations associated with antibiotic resistance are infrequently found. This protocol permits specific gene targets to be examined according to the local treatment procedures since the both antibiotics used to treat *M. tuberculosis* infections, and thus the associated antibiotic resistance mutation patterns, vary geographically. As shown in Figure 2 the culture-based methods are performed in parallel. The molecular biological methods would permit the identification of *M. tuberculosis* from both AFB smear-positive and smear-negative sputum samples and further provide information on the antibiotic resistance profile of these samples well in advance of current culture-based methods. This information would be crucial to the initiation of appropriate and effective antibiotic treatment regimens for *M. tuberculosis* infections.

Examples

A pool of DNA samples from antibiotic-sensitive *M. tuberculosis* isolates was obtained from the LCDC, Health and Welfare Canada, Ottawa, Ontario. Wild-type sequence traces, for all gene targets known to harbor mutations in antibiotic-resistant *M. tuberculosis*, were generated.

A panel of DNA samples from five phenotypic streptomycin-resistant *M. tuberculosis* isolates was obtained from the Public Health Laboratory, Ontario Ministry of Health, Toronto, Ontario. These DNA samples were examined for antibiotic resistance-associated mutations in all 10 antibiotic gene targets listed above. Streptomycin resistance-associated mutations were detected in the rpsL/s12 gene in four isolates. Parallel antibiotic resistance-associated mutations in the rpoB (rifampin), katG (isoniazid), PR (isoniazid),

embB (ethambutol), pncA (pyrazinamide) and gyrA (ciprofloxacin) genes were also identified which underscores the importance of examining all the gene targets for first-line antibiotics used in the treatment of *M. tuberculosis*. A summary of the results is shown in Table 1.

The following references are cited herein and are incorporated herein by reference for all states which allow such incorporation.

- ^a DL Williams et al. (1994). Characterisation of rifampin resistance in pathogenic mycobacteria. *Antimicrob Agents Chemother* 38: 2380-2386.
- ^b WH Haas et al. (1997). Molecular analysis of katG gene mutations in strains of *Mycobacterium tuberculosis* complex from Africa. *Antimicrob Agents Chemother* 41: 1601-1603.
- ^c S Sreevatsan et al. (1997). Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob Agents Chemother* 41: 600-606.
- ^d A Telenti et al. (1994). Genotypic assessment of isoniazid and rifampin resistance in *Mycobacterium tuberculosis*: a blind study at the reference laboratory level. *Antimicrob Agents Chemother* 35: 719-723.
- ^e C Katsukawa et al. (1997). Characterisation of the rpsL and rrs genes of streptomycin-resistant clinical isolates of *Mycobacterium tuberculosis* in Japan. *J Appl Microbiol* 83: 634-640.
- ^f C Katsukawa et al. (1997). Characterisation of the rpsL and rrs genes of streptomycin-resistant clinical isolates of *Mycobacterium tuberculosis* in Japan. *J Appl Microbiol* 83: 634-640.
- ^g MA Lety et al. (1997). A single point mutation in the embB gene is responsible for resistance to ethambutol in *Mycobacterium smegmatis*. *Antimicrob Agents Chemother* 41: 2629-2633.
- ^h A Scorpio et al. (1997). Characterisation of pncA mutations in pyrazinamide-resistant *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 41: 540-543.

- C Xu et al. (1996). Fluoroquinilone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant *Mycobacterium tuberculosis*. J Infect Disease 174: 1127-1130.**
- KA Nash et al. (1995). Genetic basis of macrolide resistance in *Mycobacterium avium* isolated from patients with disseminated disease. Antimicrob Agents Chemother 39: 2625-2630.**

T03220-20150600

Table I

gene (antibiotic)	OPH#1 bp/codon/aa	OPH#2 bp/codon/aa	OPH#3 bp/codon/aa	OPH#4 bp/codon/aa	OPH#11 bp/codon/aa
rpoB (rifampin)	cac528tac, His526Tyr	tcg553ttg, Ser653Leu	cac526gac, His526Asp	tcg553ttg, Ser653Leu	wt
katG.1 (isoniazid)	agc513acc, Ser613Thr	agc513acc, Ser613Thr	agc513acc, Ser613Thr	wt	wt
oxyR-ahpC PR (isoniazid)	g541a	wt	wt	wt	g541a
fabG (isoniazid)	wt	wt	wt	wt	wt
rpsL/s12 (streptomycin)	wt	aag43agg, Lys43Arg	aag43agg, Lys43Arg	aag68agg, Lys68Arg	aag43agg, Lys43Arg
16s/r1s (streptomycin)	wt	wt	wt	wt	wt
embB (ethambutol)	wt	gtc292tgc, val292phe	wt	wt	wt
prnA (pyrazinamide)	tc65tct, Ser65Ser	wt	att133aat, Ile133Asn	wt	tc65tct, Ser65Ser
gyrA (ciprofloxacin)	agc95acc, Ser95Thr	agc95acc, Ser95Thr	agc95acc, Ser95Thr	agc95acc, Ser95Thr	agc95acc, Ser95Thr
23s (azithromycin)	wt	wt	wt	wt	wt

CLAIMS

1. A method for detection and characterization of *Mycobacterium tuberculosis* present in a sample, comprising the steps of:
 - (a) obtaining a sputum sample suspected of containing *M. tuberculosis*,
 - (b) performing a first sequencing procedure, with or without prior amplification, on the sample, said sequencing procedure generating sequencing fragments for evaluation of the rpoB, katG, rpsL/Is12 and 23S genes for the presence of antibiotic-resistance inducing mutations when *M. tuberculosis* is present in the sample, wherein primers for the sequencing of the rpoB gene are selected such that the generation of sequencing products for this gene is indicative of the presence of *M. tuberculosis* in the sample; and
 - (c) if *M. tuberculosis* is detected as a result of generation of sequencing products for the rpoB gene in step (b), performing a second sequencing procedure, with or without prior amplification, on the sample to evaluate at least one additional *M. tuberculosis* gene for the presence of antibiotic-resistance inducing mutations.
2. The method of claim 1, wherein the second sequencing procedure evaluates PR, embB pncA and gyrA genes for the presence of antibiotic-resistance mutations.
3. The method of claim 3, further comprising the step of performing a third sequencing procedure when *M. tuberculosis* was detected in step (b), separate from the first and second sequencing procedures, to evaluate 16S/rrs and mabA genes for the presence of antibiotic-resistance mutations.
4. The method of any of claims 1 to 3, wherein the first sequencing procedure for rpoB is performed using amplification primers as set forth in Seq. ID Nos. 1 and 2 and sequencing primers as set forth in Seq. ID. Nos. 3 and 4.
5. The method of any of claims 1 to 4, wherein the first sequencing procedure for katG is performed using amplification primers as set forth in Seq. ID Nos. 6 and 7 and sequencing primers as set forth in Seq. ID. Nos. 8 and 9.

6. The method of any of claims 1 to 5, wherein the first sequencing procedure for rpsL/s12 is performed using amplification primers as set forth in Seq. ID Nos. 21 and 22 and sequencing primers as set forth in Seq. ID. Nos. 23 and 24.

7. The method of any of claims 1 to 6, wherein the second sequencing procedure for 23S is performed using amplification primers as set forth in Seq. ID Nos. 46 and 47 and sequencing primers as set forth in Seq. ID. Nos. 48 and 49.

8. The method of any of claims 1 to 7, wherein the second sequencing procedure for PR is performed using amplification primers as set forth in Seq. ID Nos. 11 and 12 and sequencing primers as set forth in Seq. ID. Nos. 13 and 14.

9. The method of any of claims 1 to 8, wherein the second sequencing procedure for pncA is performed using amplification primers as set forth in Seq. ID Nos. 36 and 37 and sequencing primers as set forth in Seq. ID. Nos. 38 and 39.

10. The method of any of claims 1 to 9, wherein the second sequencing procedure for embB is performed using amplification primers as set forth in Seq. ID Nos. 31 and 32 and sequencing primers as set forth in Seq. ID. Nos. 33 and 34.

11. The method of any of claims 1 to 10, wherein the second sequencing procedure for gyrA is performed using amplification primers as set forth in Seq. ID Nos. 41 and 42 and sequencing primers as set forth in Seq. ID. Nos. 43 and 44.

12. The method of any of claims 2 to 11, wherein the third sequencing procedure for 16S/rns is performed using amplification primers as set forth in Seq. ID Nos. 26 and 27 and sequencing primers as set forth in Seq. ID. Nos. 28 and 29.

13. The method of any of claims 2 to 12, wherein the third sequencing procedure for *mabA* is performed using amplification primers as set forth in Seq. ID Nos. 16 and 17 and sequencing primers as set forth in Seq. ID. Nos. 18 and 19.

14. A kit for evaluation of antibiotic-resistance mutations in a sample of *Mycobacterium tuberculosis*, comprising pairs of amplification primers and matched pairs of sequencing primers for amplification and sequencing the at least the *rpoB*, *katG*, *rpsL*/*s12* and *23S* genes of *M. tuberculosis*, characterized in that the amplification and sequencing primer pairs include at least one combination of primer pairs selected from among:

- (a) amplification primers of Seq. ID Nos. 1 and 2 in combination and sequencing primers of Seq. ID Nos. 3 and 4;
- (b) amplification primers of Seq. ID Nos. 6 and 7 in combination and sequencing primers of Seq. ID Nos. 8 and 9;
- (c) amplification primers of Seq. ID Nos. 11 and 12 in combination and sequencing primers of Seq. ID Nos. 13 and 14;
- (d) amplification primers of Seq. ID Nos. 16 and 17 in combination and sequencing primers of Seq. ID Nos. 18 and 19;
- (e) amplification primers of Seq. ID Nos. 21 and 22 in combination and sequencing primers of Seq. ID Nos. 23 and 24;
- (f) amplification primers of Seq. ID Nos. 26 and 27 in combination and sequencing primers of Seq. ID Nos. 28 and 29;
- (g) amplification primers of Seq. ID Nos. 31 and 32 in combination and sequencing primers of Seq. ID Nos. 33 and 34;
- (h) amplification primers of Seq. ID Nos. 36 and 37 in combination and sequencing primers of Seq. ID Nos. 38 and 39;
- (i) amplification primers of Seq. ID Nos. 41 and 42 in combination and sequencing primers of Seq. ID Nos. 43 and 44; and
- (j) amplification primers of Seq. ID Nos. 46 and 47 in combination and sequencing primers of Seq. ID Nos. 48 and 49.

Figure 1





Figure 2



Feb-23-01 02:56P NoAb Diagnostics
02/23/2001 12:29 9784680184905 814 5241
OPPEDAHL & LARSON LLPP.04
PAGE 83/84**COMBINED DECLARATION
AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My citizenship, residence and post office address are as listed below next to my name.

I believe I am the original, first and [x] sole/[] joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: Method and Kit for Characterization of Antibiotic-Resistance Mutations in Mycobacterium Tuberculosis

the specification of which

(a) [] Is attached hereto.

(b) [] was filed on _____ as Application Serial No. _____ and was amended on _____

(c) [x] was described and claimed in International Application No. PCT/CA98/01177 filed on December 10, 1998 and amended on _____

Acknowledgment of Duty of Disclosure

I hereby state that I have reviewed and understood the content of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56(a).

35 U.S.C. § 120

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or 365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status)(patented,pending,abandoned)	(Patent No. if applicable)
(Application Serial No.)	(Filing Date)	(Status)(patented,pending,abandoned)	(Patent No. if applicable)

(Application Serial No.)	(Filing Date)	(Status)(patented,pending,abandoned)	(Patent No. if applicable)
(Application Serial No.)	(Filing Date)	(Status)(patented,pending,abandoned)	(Patent No. if applicable)

Power of Attorney

I hereby appoint Carl Oppedahl, PTO Reg. NO. 32,746 and Marina T. Larson, PTO Reg. No. 32,038, and D'Arcy Straub, PTO Reg. No. 47,113, of the firm of OPPEDAHL & LARSON LLP, having office at P.O. Box 5068, Dillon, Colorado 80435-5068, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:



021121

PATENT TRADemark OFFICE

DIRECT TELEPHONE CALLS TO:

OPPEDAHL & LARSON LLP
(970)488-0600

Feb-23-01 02:57P NoAb Diagnostics

905 814 5241

P.05

02/23/2001 12:29 9704680104

OPPEDAH & LARSON LLP

PAGE 04/04

Claim for Priority

I hereby claim foreign priority benefits under 35 U.S.C. § 118 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 386(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign applications for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

EARLIEST FOREIGN APPLICATION(S), FILED WITHIN TWELVE MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION					
COUNTRY	APPLICATION NO.	DATE OF FILING (day/month/year)	DATE OF ISSUE (day/month/year)	PRIORITY CLAIMED	CERTIFIED COPY ATTACHED
				YES () NO ()	YES () NO ()

FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION					
COUNTRY	APPLICATION NO.	DATE OF FILING (day/month/year)	DATE OF ISSUE (day/month/year)		

Provisional Application

I hereby claim the benefit under 35 U.S.C. § 118(e) of any United States provisional application(s) listed below.

50/111,796

December 11, 1999

(application number)

(filing date)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR	LAST NAME SHIPMAN	FIRST NAME ROBERT	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY OF RESIDENCE Mississauga	STATE OR COUNTRY OF RESIDENCE Ontario, Canada	COUNTRY OF CITIZENSHIP Canada
POST OFFICE ADDRESS 130 Vista Boulevard		CITY Mississauga, Ontario	STATE/COUNTRY ZIP CODE Canada L5M 1V8
DATE FEB. 23, 2001		SIGNATURE R. Shipman	

- 1) Signature for additional joint inventor attached. Number of Pages ____
- 1) Signature by Administrator(s) or legal representative for deceased or incapacitated inventor. Number of Pages ____
- 1) Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR § 1.47. Number of Pages ____

00765105.022601